JP2013510853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510853A5 JP2013510853A5 JP2012538863A JP2012538863A JP2013510853A5 JP 2013510853 A5 JP2013510853 A5 JP 2013510853A5 JP 2012538863 A JP2012538863 A JP 2012538863A JP 2012538863 A JP2012538863 A JP 2012538863A JP 2013510853 A5 JP2013510853 A5 JP 2013510853A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazol
- azabicyclo
- amino
- carbamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 (2S) -2- (5- (7- (2-((2S) -1-((2S) -2-((methoxycarbonyl) amino) -3-methyl Butanoyl) -2-pyrrolidinyl) -1H-benzimidazol-5-yl) -2-naphthyl) -1H-benzimidazol-2-yl) -1-pyrrolidinyl Chemical group 0.000 claims 164
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 130
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 86
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 72
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 108010050904 Interferons Proteins 0.000 claims 8
- 102000014150 Interferons Human genes 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- QPTTYIGXMQFXIZ-FJZBIBNSSA-N (2r)-2-phenyl-1-[(2s)-2-[6-[6-[2-[(2s)-1-[(2r)-2-phenyl-2-piperidin-1-ylacetyl]pyrrolidin-2-yl]-3h-benzimidazol-5-yl]naphthalen-2-yl]-1h-benzimidazol-2-yl]pyrrolidin-1-yl]-2-piperidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC3=CC=C(C=C3N=2)C=2C=C3C=CC(=CC3=CC=2)C=2C=C3N=C(NC3=CC=2)[C@H]2N(CCC2)C(=O)[C@H](N2CCCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCCC1 QPTTYIGXMQFXIZ-FJZBIBNSSA-N 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 2
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 150000004712 monophosphates Chemical class 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- XJKLOZJUFFQPCQ-FJZBIBNSSA-N (2r)-2-phenyl-1-[(2s)-2-[6-[7-[2-[(2s)-1-[(2r)-2-phenyl-2-piperidin-1-ylacetyl]pyrrolidin-2-yl]-3h-benzimidazol-5-yl]naphthalen-2-yl]-1h-benzimidazol-2-yl]pyrrolidin-1-yl]-2-piperidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC3=CC=C(C=C3N=2)C=2C=C3C=C(C=CC3=CC=2)C=2C=C3N=C(NC3=CC=2)[C@H]2N(CCC2)C(=O)[C@H](N2CCCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCCC1 XJKLOZJUFFQPCQ-FJZBIBNSSA-N 0.000 claims 1
- JHMWCRILHMZZDK-OEZRKNEGSA-N 1-[(2s,5s)-2-[5-[4-[6-[2-[(2s,5s)-1-acetyl-5-methylpyrrolidin-2-yl]-1h-imidazol-5-yl]naphthalen-2-yl]phenyl]-1h-imidazol-2-yl]-5-methylpyrrolidin-1-yl]ethanone Chemical compound CC(=O)N1[C@@H](C)CC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=C3C=CC(=CC3=CC=2)C=2N=C(NC=2)[C@H]2N([C@@H](C)CC2)C(C)=O)=CN1 JHMWCRILHMZZDK-OEZRKNEGSA-N 0.000 claims 1
- ZCVAUEFQQGJOAF-BFCBZKQHSA-N 3-methyl-1-[(2s,4s)-4-methyl-2-[5-[4-[6-[2-[(2s,4s)-4-methyl-1-(3-methylbutanoyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]naphthalen-2-yl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]butan-1-one Chemical compound CC(C)CC(=O)N1C[C@@H](C)C[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=C3C=CC(=CC3=CC=2)C=2N=C(NC=2)[C@H]2N(C[C@@H](C)C2)C(=O)CC(C)C)=CN1 ZCVAUEFQQGJOAF-BFCBZKQHSA-N 0.000 claims 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- IIYZHZDLGGHLBE-ZQWQDMLBSA-N methyl n-[(2s)-1-[(2s)-2-[5-[4-[6-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]naphthalen-2-yl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=C3C=CC(=CC3=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)N1 IIYZHZDLGGHLBE-ZQWQDMLBSA-N 0.000 claims 1
- LCHMHYPWGWYXEL-ZYADHFCISA-N methyl n-[(2s)-1-[(2s)-2-[5-[6-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3h-benzimidazol-5-yl]naphthalen-2-yl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=C3C=CC(=CC3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)N1 LCHMHYPWGWYXEL-ZYADHFCISA-N 0.000 claims 1
- LTRAHHIJHWEYPT-ZYADHFCISA-N methyl n-[(2s)-1-[(2s)-2-[5-[7-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3h-benzimidazol-5-yl]naphthalen-2-yl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=C3C=C(C=CC3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)N1 LTRAHHIJHWEYPT-ZYADHFCISA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26011509P | 2009-11-11 | 2009-11-11 | |
| US61/260,115 | 2009-11-11 | ||
| US37880610P | 2010-08-31 | 2010-08-31 | |
| US61/378,806 | 2010-08-31 | ||
| PCT/US2010/055565 WO2011059887A1 (en) | 2009-11-11 | 2010-11-05 | Hepatitis c virus inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510853A JP2013510853A (ja) | 2013-03-28 |
| JP2013510853A5 true JP2013510853A5 (OSRAM) | 2013-11-28 |
Family
ID=43466793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538863A Pending JP2013510853A (ja) | 2009-11-11 | 2010-11-05 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20110274648A1 (OSRAM) |
| EP (1) | EP2499127B1 (OSRAM) |
| JP (1) | JP2013510853A (OSRAM) |
| KR (1) | KR20130036173A (OSRAM) |
| CN (1) | CN102712623B (OSRAM) |
| AR (1) | AR078976A1 (OSRAM) |
| AU (1) | AU2010319801A1 (OSRAM) |
| BR (1) | BR112012011100A2 (OSRAM) |
| CA (1) | CA2780812A1 (OSRAM) |
| CL (1) | CL2012001230A1 (OSRAM) |
| EA (1) | EA201270622A1 (OSRAM) |
| ES (1) | ES2690660T3 (OSRAM) |
| IL (1) | IL219516A (OSRAM) |
| MA (1) | MA33731B1 (OSRAM) |
| MX (1) | MX2012005190A (OSRAM) |
| NZ (1) | NZ600505A (OSRAM) |
| PE (1) | PE20121354A1 (OSRAM) |
| PH (1) | PH12012500922A1 (OSRAM) |
| TN (1) | TN2012000214A1 (OSRAM) |
| TW (1) | TWI475019B (OSRAM) |
| WO (1) | WO2011059887A1 (OSRAM) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5762971B2 (ja) | 2008-12-03 | 2015-08-12 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| EP2367823A1 (en) | 2008-12-23 | 2011-09-28 | Abbott Laboratories | Anti-viral compounds |
| MX2011006332A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG175144A1 (en) * | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
| BRPI1010795B1 (pt) | 2009-05-13 | 2018-12-11 | Gilead Pharmasset Llc | compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20110679A1 (es) | 2009-06-11 | 2011-10-20 | Abbvie Bahamas Ltd | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| CN102656160A (zh) | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2512480A4 (en) * | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20130244A1 (es) | 2010-01-25 | 2013-03-10 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2550262A1 (en) * | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| JP5894980B2 (ja) * | 2010-05-24 | 2016-03-30 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8486938B2 (en) | 2010-06-24 | 2013-07-16 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines for antiviral treatment |
| US8697704B2 (en) | 2010-08-12 | 2014-04-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
| CA2841095A1 (en) | 2011-07-09 | 2013-01-17 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
| WO2013025975A1 (en) * | 2011-08-17 | 2013-02-21 | Glaxosmithkline Llc | Combination treatments for hepatitis c |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| AP2014007575A0 (en) | 2011-09-16 | 2012-04-30 | Gilead Pharmasset Llc | Methods for treating HCV |
| CA2852700A1 (en) | 2011-11-03 | 2013-05-10 | Theravance, Inc. | Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(biphenyl-4-yl)-1h-imidazo-2-yl]pyrrolidine-1-carbonlymethyl}amine |
| EP2794611B1 (en) | 2011-12-22 | 2017-10-11 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| EA027855B1 (ru) | 2012-04-17 | 2017-09-29 | Гайлид Сайэнсиз, Инк. | Соединения и способы для противовирусной терапии |
| ES2624846T3 (es) | 2012-04-25 | 2017-07-17 | Theravance Biopharma R&D Ip, Llc | Compuestos de piperazina-piperidina como inhibidores del virus de la hepatitis C |
| JP6006008B2 (ja) * | 2012-06-14 | 2016-10-12 | ユー・ディー・シー アイルランド リミテッド | 化合物、有機電界発光素子並びに該有機電界発光素子を用いた発光装置、表示装置及び照明装置 |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| CN103848821B (zh) | 2012-11-29 | 2016-10-12 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途 |
| CN103848818B (zh) | 2012-11-29 | 2017-03-15 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用 |
| SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN104803989B (zh) | 2014-01-23 | 2017-12-22 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用 |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| CN108137514A (zh) * | 2015-07-30 | 2018-06-08 | 百时美施贵宝公司 | 芳基取代的二环杂芳基化合物 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP3597646B1 (en) | 2016-08-19 | 2023-06-21 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| US10696657B2 (en) | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
| TWI842721B (zh) | 2018-07-16 | 2024-05-21 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| TW202502766A (zh) | 2020-06-25 | 2025-01-16 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| CN117460734A (zh) | 2021-05-21 | 2024-01-26 | 吉利德科学公司 | 作为寨卡病毒抑制剂的五环衍生物 |
| CN117321059A (zh) | 2021-05-21 | 2023-12-29 | 吉利德科学公司 | 用于治疗寨卡病毒感染的四环化合物 |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CN118369316A (zh) | 2021-12-03 | 2024-07-19 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2153987A1 (en) | 1993-01-14 | 1994-07-21 | U. Prasad Kari | Amino acids and peptides having modified terminals |
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| EP1532118A2 (en) | 2002-07-05 | 2005-05-25 | Axxima Pharmaceuticals Aktiengesellschaft | Imidazole compounds for the treatment of hepatitis c virus infections |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| US7894996B2 (en) | 2005-02-28 | 2011-02-22 | The Rockefeller University | Structure of the hepatitis C NS5A protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2006290442B2 (en) | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| ES2395386T3 (es) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Compuestos antivirales |
| NZ569817A (en) | 2005-12-21 | 2011-10-28 | Abbott Lab | Anti-viral compounds |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| MX2008014990A (es) | 2006-05-30 | 2008-12-09 | Arrow Therapeutics Ltd | Derivados de bifenilo y su uso en el tratamiento de hepatitis c. |
| CA2672267C (en) | 2006-07-27 | 2016-05-31 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
| US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070447A2 (en) | 2006-11-21 | 2008-06-12 | Smithkline Beecham Corporation | Anti-viral compounds |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| DE102007057622A1 (de) * | 2007-11-30 | 2009-06-04 | Stechert Stahlrohrmöbel GmbH | Klappstuhl |
| PT2250163E (pt) | 2008-02-12 | 2012-06-01 | Bristol Myers Squibb Co | Inibidores do vírus da hepatite c |
| KR20100123717A (ko) | 2008-02-12 | 2010-11-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체 |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DK2242752T3 (da) | 2008-02-13 | 2012-11-19 | Bristol Myers Squibb Co | Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| JP5762971B2 (ja) * | 2008-12-03 | 2015-08-12 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| AU2009322400A1 (en) * | 2008-12-03 | 2011-06-30 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| MX2011006332A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| CA2753382C (en) * | 2009-02-27 | 2014-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
| CN109651342A (zh) | 2009-03-27 | 2019-04-19 | 默沙东公司 | 丙型肝炎病毒复制的抑制剂 |
| US20110237636A1 (en) | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG175144A1 (en) | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
| BRPI1016172A2 (pt) | 2009-04-24 | 2016-04-19 | Tibotec Pharm Ltd | éteres diarílicos |
| EP2430015B1 (en) | 2009-05-12 | 2015-06-17 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds useful for the treatment of viral diseases |
| BRPI1010795B1 (pt) * | 2009-05-13 | 2018-12-11 | Gilead Pharmasset Llc | compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010138790A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| PE20110679A1 (es) | 2009-06-11 | 2011-10-20 | Abbvie Bahamas Ltd | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| CN102656160A (zh) | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
| EP2462136A1 (en) | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
| EP2462135A1 (en) | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
| BR112012004969A2 (pt) | 2009-09-03 | 2019-09-24 | Tibotec Pharm Ltd | derivados de bis-benzimidazol |
| CN102480971B (zh) | 2009-09-04 | 2014-11-26 | 杨森制药公司 | 化合物 |
| WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
| UA108211C2 (uk) * | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| AU2010325980B2 (en) | 2009-12-04 | 2016-04-07 | National Health Research Institutes | Proline derivatives |
| EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20110152246A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| RU2554087C2 (ru) | 2009-12-18 | 2015-06-27 | Айденикс Фармасьютикалз, Инк. | 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с |
| JP2013515068A (ja) | 2009-12-22 | 2013-05-02 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法 |
| WO2011079327A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| PE20130244A1 (es) | 2010-01-25 | 2013-03-10 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c |
| EP2528926A4 (en) | 2010-01-28 | 2013-06-19 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
| MX2012010918A (es) * | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| EP2575866A4 (en) * | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
| US20120196794A1 (en) | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2010
- 2010-11-04 US US12/939,778 patent/US20110274648A1/en not_active Abandoned
- 2010-11-05 JP JP2012538863A patent/JP2013510853A/ja active Pending
- 2010-11-05 PE PE2012000637A patent/PE20121354A1/es not_active Application Discontinuation
- 2010-11-05 KR KR1020127014909A patent/KR20130036173A/ko not_active Withdrawn
- 2010-11-05 EA EA201270622A patent/EA201270622A1/ru unknown
- 2010-11-05 MX MX2012005190A patent/MX2012005190A/es not_active Application Discontinuation
- 2010-11-05 ES ES10779605.4T patent/ES2690660T3/es active Active
- 2010-11-05 CA CA2780812A patent/CA2780812A1/en not_active Abandoned
- 2010-11-05 EP EP10779605.4A patent/EP2499127B1/en not_active Not-in-force
- 2010-11-05 BR BR112012011100A patent/BR112012011100A2/pt not_active IP Right Cessation
- 2010-11-05 AU AU2010319801A patent/AU2010319801A1/en not_active Abandoned
- 2010-11-05 NZ NZ600505A patent/NZ600505A/en not_active IP Right Cessation
- 2010-11-05 WO PCT/US2010/055565 patent/WO2011059887A1/en not_active Ceased
- 2010-11-05 CN CN201080061186.1A patent/CN102712623B/zh not_active Expired - Fee Related
- 2010-11-05 PH PH1/2012/500922A patent/PH12012500922A1/en unknown
- 2010-11-11 TW TW099138879A patent/TWI475019B/zh not_active IP Right Cessation
- 2010-11-11 AR ARP100104186A patent/AR078976A1/es unknown
-
2012
- 2012-05-01 IL IL219516A patent/IL219516A/en not_active IP Right Cessation
- 2012-05-07 MA MA34842A patent/MA33731B1/fr unknown
- 2012-05-10 CL CL2012001230A patent/CL2012001230A1/es unknown
- 2012-05-11 TN TNP2012000214A patent/TN2012000214A1/en unknown
- 2012-11-08 US US13/672,266 patent/US20130115193A1/en not_active Abandoned
-
2015
- 2015-03-25 US US14/668,090 patent/US20150197499A1/en not_active Abandoned
- 2015-07-23 US US14/806,964 patent/US9303007B2/en active Active
- 2015-07-23 US US14/807,084 patent/US9776981B2/en active Active
-
2017
- 2017-08-29 US US15/689,286 patent/US20170355689A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510853A5 (OSRAM) | ||
| JP2012523415A5 (OSRAM) | ||
| JP2011530531A5 (OSRAM) | ||
| JP2012518000A5 (OSRAM) | ||
| JP2012528161A5 (OSRAM) | ||
| JP2013532725A5 (OSRAM) | ||
| HRP20120706T1 (hr) | Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c | |
| JP2010500413A5 (OSRAM) | ||
| JP2014513690A5 (OSRAM) | ||
| JP2010500414A5 (OSRAM) | ||
| JP2012522056A5 (OSRAM) | ||
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| KR101730681B1 (ko) | Ｃ형 간염 바이러스 억제제 | |
| JP2012522053A5 (OSRAM) | ||
| HRP20140737T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2013510857A5 (OSRAM) | ||
| US8426458B2 (en) | Hepatitis C Virus inhibitors | |
| US10017499B2 (en) | Benzimidazole derivatives | |
| NZ594068A (en) | Substituted benzimidazole compounds as hepatitis c virus inhibitors | |
| JP2010500415A5 (OSRAM) | ||
| RU2540897C2 (ru) | Производные бис-бензимидазола в качестве ингибиторов вируса гепатита с | |
| JP2014504643A5 (OSRAM) | ||
| US8815849B2 (en) | Hetero-bicyclic derivatives as HCV inhibitors | |
| JP2012523457A5 (OSRAM) | ||
| JP2015529652A5 (OSRAM) |